← Back to all trials
Not Yet Recruiting
NCT07599579
Mobile Health Program for Post-Preeclampsia Hypertension
Conditions: Hypertension (HTN), Preeclampsia, Hypertensive Disorders of Pregnancy (HDP)
Sex: Female
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 50
Sponsor: University of Pittsburgh
Location: UPMC Magee Womens Hospital Pittsburgh Pennsylvania
Summary
Strategies targeted to optimize hypertension (HTN) control for midlife women after hypertensive disorders of pregnancy (HDP) have not been studied, despite evidence of a critical need. This proposal targets the 10-20 years postpartum as a key time when women have subclinical cardiovascular (CV) sequelae of uncontrolled HTN and are primed for CV prevention interventions. Before proceeding with large-scale intervention trials of a home blood pressure monitoring (HBPM) and coaching intervention following HDP, further pilot testing is necessary. The overarching hypothesis of this proposal is that a new monitoring and treatment paradigm utilizing HBPM combined with a virtual coaching intervention would be better than standard of care for mid-life women with prior HDP who develop HTN. Women will be assigned in an unblinded manner to the intervention or standard of care control group.
Eligibility Criteria
Inclusion Criteria:
* Women who had a history of HDP (either gestational HTN or preeclampsia) diagnosed by ACOG guidelines at the time of delivery at Magee-Womens Hospital between 2008 and 2015, thus 10 to 20 years from their index pregnancy complicated by HDP.
* Evidence of current stage 2 HTN (BP ≥ 140/90 mmHg with or without treatment with antihypertensive medication).
Exclusion Criteria:
* Known clinical CVD (prior myocardial infarction, stroke, heart failure, or peripheral arterial disease).
* Males will also be excluded from this study as it focuses on pregnancy related conditions.
* Children will be excluded as the study is only recruiting people who are 10-20 years postpartum.
Source: ClinicalTrials.gov (NCT07599579). StuddyBuddy aggregates publicly available trial information.